Zacks Research Weighs in on Dr. Reddy’s Laboratories Limited’s Q2 2026 Earnings (NYSE:RDY)

Dr. Reddy’s Laboratories Limited (NYSE:RDY) – Investment analysts at Zacks Research increased their Q2 2026 earnings per share (EPS) estimates for Dr. Reddy’s Laboratories in a research report issued to clients and investors on Wednesday, August 14th. Zacks Research analyst R. Department now anticipates that the company will earn $0.99 per share for the quarter, up from their prior estimate of $0.98. The consensus estimate for Dr. Reddy’s Laboratories’ current full-year earnings is $4.13 per share. Zacks Research also issued estimates for Dr. Reddy’s Laboratories’ Q3 2026 earnings at $1.00 EPS, Q4 2026 earnings at $1.04 EPS and FY2026 earnings at $4.05 EPS.

Dr. Reddy’s Laboratories (NYSE:RDY) last announced its earnings results on Saturday, July 27th. The company reported $1.00 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $1.10 by ($0.10). The business had revenue of $919.80 million for the quarter, compared to analysts’ expectations of $861.68 million. Dr. Reddy’s Laboratories had a net margin of 19.28% and a return on equity of 20.32%.

Other research analysts have also issued reports about the stock. StockNews.com lowered shares of Dr. Reddy’s Laboratories from a “strong-buy” rating to a “buy” rating in a research note on Thursday, May 16th. Barclays raised their target price on Dr. Reddy’s Laboratories from $81.00 to $87.00 and gave the company an “overweight” rating in a research report on Tuesday, July 30th.

Dr. Reddy’s Laboratories Stock Performance

RDY opened at $83.18 on Monday. The firm’s fifty day simple moving average is $77.97 and its two-hundred day simple moving average is $74.76. Dr. Reddy’s Laboratories has a 52-week low of $63.72 and a 52-week high of $84.46. The company has a market cap of $13.88 billion, a price-to-earnings ratio of 20.64, a PEG ratio of 1.81 and a beta of 0.56. The company has a quick ratio of 1.92, a current ratio of 2.55 and a debt-to-equity ratio of 0.02.

Hedge Funds Weigh In On Dr. Reddy’s Laboratories

A number of institutional investors and hedge funds have recently bought and sold shares of the business. Millennium Management LLC lifted its stake in Dr. Reddy’s Laboratories by 61.4% in the 2nd quarter. Millennium Management LLC now owns 332,502 shares of the company’s stock worth $25,333,000 after purchasing an additional 126,472 shares in the last quarter. Schroder Investment Management Group boosted its stake in Dr. Reddy’s Laboratories by 77.6% during the fourth quarter. Schroder Investment Management Group now owns 266,653 shares of the company’s stock worth $18,554,000 after buying an additional 116,488 shares during the last quarter. Fisher Asset Management LLC boosted its stake in Dr. Reddy’s Laboratories by 126.5% during the fourth quarter. Fisher Asset Management LLC now owns 205,280 shares of the company’s stock worth $14,283,000 after buying an additional 114,630 shares during the last quarter. Dimensional Fund Advisors LP grew its holdings in Dr. Reddy’s Laboratories by 12.8% in the 2nd quarter. Dimensional Fund Advisors LP now owns 1,003,782 shares of the company’s stock valued at $76,455,000 after buying an additional 114,294 shares in the last quarter. Finally, Jane Street Group LLC increased its stake in shares of Dr. Reddy’s Laboratories by 2,197.8% in the 1st quarter. Jane Street Group LLC now owns 113,168 shares of the company’s stock worth $8,301,000 after acquiring an additional 108,243 shares during the last quarter. 14.02% of the stock is currently owned by institutional investors and hedge funds.

About Dr. Reddy’s Laboratories

Dr. Reddy's Laboratories Limited, together with its subsidiaries, operates as an integrated pharmaceutical company worldwide. It operates through Global Generics, Pharmaceutical Services and Active Ingredients (PSAI), and Others segments. The company's Global Generics segment manufactures and markets prescription and over-the-counter finished pharmaceutical products that are marketed under a brand name or as a generic finished dosages with therapeutic equivalence to branded formulations.